Patents by Inventor Michael C. Myers

Michael C. Myers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF
    Publication number: 20220331402
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Application
    Filed: April 15, 2022
    Publication date: October 20, 2022
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • APELIN RECEPTOR AGONISTS AND METHODS OF USE
    Publication number: 20220315569
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Application
    Filed: June 9, 2022
    Publication date: October 6, 2022
    Inventors: Wei Meng, Hannguang J. Chao, Heather Finlay, R. Michael Lawrence, Michael C. Myers
  • Apelin receptor agonists and methods of use
    Patent number: 11390616
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 19, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wei Meng, Hannguang J. Chao, Heather Finlay, R. Michael Lawrence, Michael C. Myers
  • MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF
    Publication number: 20220211812
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Application
    Filed: January 11, 2022
    Publication date: July 7, 2022
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof
    Patent number: 11364281
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: June 21, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof
    Patent number: 11224634
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: January 18, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides
    Patent number: 11185570
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: November 30, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF
    Publication number: 20210196791
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Application
    Filed: March 11, 2021
    Publication date: July 1, 2021
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • APELIN RECEPTOR AGONISTS AND METHODS OF USE
    Publication number: 20210198246
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Application
    Filed: December 2, 2016
    Publication date: July 1, 2021
    Inventors: Wei Meng, Hannguang J. Chao, Heather Finlay, R. Michael Lawrence, Michael C. Myers
  • Heteroarylhydroxypyrimidinones as agonists of the APJ receptor
    Patent number: 10669261
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments, in particular for treating cardiovascular disorders.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: June 2, 2020
    Assignee: Bristl-Myers Squibb Company
    Inventors: Michael C. Myers, R. Michael Lawrence, Donna M. Bilder, Wei Meng, Zulan Pi, Robert Paul Brigance, Heather Finlay
  • 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists
    Patent number: 10590113
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: March 17, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zulan Pi, Donna M. Bilder, Robert Paul Brigance, Heather Finlay, Wen Jiang, James A. Johnson, R. Michael Lawrence, Wei Meng, Michael C. Myers, Monique Phillips, George O. Tora, Xiaojun Zhang
  • 4-HYDROXY-3-(HETEROARYL)PYRIDINE-2-ONE APJ AGONISTS
    Publication number: 20190263791
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Application
    Filed: May 14, 2019
    Publication date: August 29, 2019
    Inventors: James A. Johnson, Soong-Hoon Kim, R. Michael Lawrence, Michael C. Myers, Hannguang J. Chao, Monique Phillips, Ji Jiang
  • 2,4-dihydroxy-nicotinamides as APJ agonists
    Patent number: 10392347
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: August 27, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Soong-Hoon Kim, Hannguang J. Chao, Heather Finlay, Ji Jiang, James A. Johnson, R. Michael Lawrence, Michael C. Myers, Monique Phillips, George O. Tora, Wei Meng
  • MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF
    Publication number: 20190256570
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Application
    Filed: February 27, 2019
    Publication date: August 22, 2019
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
    Patent number: 10266578
    Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: April 23, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gene M. Dubowchik, Olafur S. Gudmundsson, Xiaojun Han, R. Michael Lawrence, Dasa Lipovsek, Cort S. Madsen, Claudio Mapelli, Paul E. Morin, Michael C. Myers
  • 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS
    Publication number: 20190002441
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Application
    Filed: September 6, 2018
    Publication date: January 3, 2019
    Inventors: Zulan Pi, Donna M. Bilder, Robert Paul Brigance, Heather Finlay, Wen Jiang, James A. Johnson, R. Michael Lawrence, Wei Meng, Michael C. Myers, Monique Phillips, George O. Tora, Xiaojun Zhang
  • HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR
    Publication number: 20180362508
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments, in particular for treating cardiovascular disorders.
    Type: Application
    Filed: December 15, 2016
    Publication date: December 20, 2018
    Inventors: Michael C. Myers, R. Michael Lawrence, Donna M. Bilder, Wei Meng, Zulan Pi, Robert Paul Brigance, Heather Finlay
  • 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists
    Patent number: 10106528
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: October 23, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zulan Pi, Donna M. Bilder, Robert Paul Brigance, Heather Finlay, Wen Jiang, James A. Johnson, R. Michael Lawrence, Wei Meng, Michael C. Myers, Monique Phillips, George O. Tora, Xiaojun Zhang
  • 2,4-DIHYDROXY-NICOTINAMIDES AS APJ AGONISTS
    Publication number: 20180297954
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, O and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Application
    Filed: October 13, 2016
    Publication date: October 18, 2018
    Inventors: Soong-Hoon Kim, Hannguang J. Chao, Heather Finlay, Ji Jang, James A. Johnson, R. Michael Lawrence, Michael C. Myers, Monique Phillips, George O. Tora, Wei Meng
  • 4-HYDROXY-3-(HETEROARYL)PYRIDINE-2-ONE APJ AGONISTS
    Publication number: 20180273518
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Application
    Filed: May 29, 2018
    Publication date: September 27, 2018
    Inventors: James A. Johnson, Soong-Hoon Kim, R. Michael Lawrence, Michael C. Myers, Hannguang J. Chao, Monique Phillips, Ji Jiang